No FDA-approved rapid tests exist that specifically test for H5N1, and the first near-point-of-care test for mpox was ...

Last week, I was about to go on a date, and because I'm severely immunocompromised, we agreed he would take a COVID test using one of my rapid home PCR tests. It was a courtesy—he felt perfectly ...

BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...

To obtain your free test kits, visit www.covidtests.gov. Yes. Original Medicare covers the updated (2023 to 2024) Moderna or Pfizer-BioNTech COVID-19 vaccine. You’ll pay nothing for the vaccine ...

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech ... are hoping the same rapid development and deployment ...

Despite their modest sensitivity, because of their rapid turnaround time, RIDTs could occupy a place at the point-of-care that more accurate tests, such as RT-PCR, are currently unable to fill.

John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...

16 analysts have expressed a variety of opinions on BioNTech BNTX over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...

In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...

BioNTech SE reported a surprise profit in the third quarter, helped by solid sales of its variant-adapted Covid-19 vaccines. Mainz, Germany-based BioNTech posted earnings of €0.81 ($0.88) per ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing varying results among patients. The hold impacts an open-label trial ...

BioNTech exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates ...